While clinical trials have not extended to brain diseases, antiangiogenesis therapy for the treatment of brain tumors may be more effective if a combination of both VEGF-A and -D inhibitors are used or if inhibitors of VEGFR-2 are used, as this receptor is activated by both VEGF-A and VEGF-D. The gene discussed is VEGFD; the disease is brain neoplasm.